Kornimate/medical-research-clean huggingface dataset:
gait analysis and clinical outcomes of anterior and lateral approach total hip arthroplasty.

Conditions: Hip Osteoarthritis

Summary: the goal of this prospective randomized study is to confirm presence or absence of differences in gait mechanics in direct anterior and lateral approaches for total hip arthroplasty. and to compare the clinical outcomes of both approaches. the main questions it aims to answer are: if the anterior approach to the hip is faster recovery than lateral approach? if the anterior approach to the hip has better gait mechanics than lateral approach? participants will: undergo one of the two approaches for total hip arthroplasty. all patients will be followed up at 2 weeks, 6 weeks, 3 months and 18 months. gait analysis will be done at 6wks, 3m, and 18months.


Eligibility criteria:
inclusion criteria: * patients with primary osteoarthritis or osteonecrosis of the hip who consented for treatment with a total hip arthroplasty (tha) through an anterior or lateral approach. * age between 20 - 60 years of age. * the participant had to be independent and physically active, which characterized as having the capacity to carry out daily tasks, ascend two flights of stairs, and able to walk for 15 minutes. exclusion criteria: * patients with bilateral hip affection. * body mass index (bmi) greater than 40. * diagnosis other than primary osteoarthritis or osteonecrosis. * prior hip or spine surgery. * chronic uncontrolled comorbidities, psychological disorders. * american society of anaesthesiologists score (asa) higher than 2 * chronic neurological deficits that influence gait. * any limb length discrepancy more than 1 cm. * any postoperative complication that will lead to delay in weight bearing.

Keywords: arthroplasty
study evaluating ppm-204 in subjects with type 2 diabetes

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to learn whether ppm-204 has an effect on lowering blood glucose (blood sugar) levels and is safe in treating people with type 2 diabetes.

the objectives of the study are to identify doses of ppm-204 that are therapeutically effective and well tolerated in improving glycemic control over 24 weeks of treatment in subjects with type 2 diabetes mellitus (t2dm).

Eligibility criteria:
inclusion criteria: * men and women of non-childbearing potential, 18 to 70 years old * subjects currently treated with diet and exercise alone and subjects receiving a single oral antidiabetic medication * bmi \> 23 and \< 43 * for subjects currently treated with 1 antidiabetic medication: hba1c is greater than or equal to 6.8% and less than or equal to 8.5%. * for subjects not currently treated with antidiabetic medications: hba1c is greater than or equal to 7.2% and less than or equal to 9.0% exclusion criteria: * subjects requiring insulin therapy * subjects currently receiving 2 or more oral antidiabetic medications * subjects requiring systemic corticosteroids, unless treatment was discontinued at least 4 weeks before the screening visit * subjects receiving warfarin * subjects currently receiving thiazolidinediones, unless treatment was discontinued 8 weeks before the screening visit * significant diabetic complications (retinopathy, nephropathy, symptomatic neuropathy)

Keywords: type 2 diabetes diabetes
effects of creatine and rehabilitation programin athletes with patellar tendinopathy

Conditions: Creatine; Patellar Tendinopathy

Summary: the aim of this study are to analyze the effect of creatine ingestion in pain, histological properties of the tendon, body composition, strength and vertical jump performance in athletes with patellar tendinopathy that follow a physical rehabilitation program that include eccentric exercise combined with stretching and extracorporeal shock wave therapy.

nutrition could play an important role in the rehabilitation from sport injuries. this afirmation is based on studies that analyze the impact of different dietary supplements along immobilization periods, stablishing that creatine, leucine and omega-3 fatty acid supplementation could ameliorate muscle loss, while creatine could potentiate the hypertrophy along the rehabilitation process. for this reason, the aim of this study are to analyze the effect of creatine ingestion in pain, histological properties of the tendon, body composition, strength and vertical jump performance in athletes with patellar tendinopathy that follow a physical rehabilitation program that include eccentric exercise combined with stretching and extracorporeal shock wave therapy.

Eligibility criteria:
inclusion criteria: * athletes diagnosed with patellar tendinopathy by sport medicine doctor. * age (\>18 years and \<49 years). * to be federated in a sport modality that involves high repetitive impact in the knee; iii) to train more than 3 sessions weekly. * not having undergone knee surgery. * not having undergone any infiltration of analgesics or platelet-rich plasma during the last year. * not intake any sport performance supplement in the previous year; * smoker person. exclusion criteria: * not being diagnosed with patellar tendinopathy by a doctor * age (\ 50 years). * involved in a sport modality without high repetitive impacts during sports activity.

Keywords: ergogenic aid dietary injury nutrition sport nutrition
a comparative analysis on physical activity performance and motor function of affected upper extremity before and after a cimt program in young children with hemiparetic cerebral palsy

Conditions: Hemiplegic Cerebral Palsy With Spasticity (Diagnosis)

Summary: this study evaluates cimt(constraint induced movement therapy) in the treatment of physical activity performance and motor function of the weaker extremity in young children with cerebral palsy. half of participants will receive cimt while the other half will receive no treatment.

constraint-induced movement therapy (cimt) is a short-term, intensive treatment to promote functional arm and hand skills in people with hemiparesis. it usually involves constraint of the non-involved extremity and intensive movement practice of the weaker extremity.

Eligibility criteria:
inclusion criteria: * diagnosed with spastic hemiplegic cerebral palsy * age between 18 months and 36 months * mini-macs level 1-4 exclusion criteria: * botox injection in upper extremity within 6 months * poor cooperation with cognitive impairment * any musculoskeletal disease * visual or hearing impairment * uncontrollable epilepsy * skin damage that makes impossible for participant to wear a splint * mini-macs level 5
comparing post-transplant cyclophosphamide as gvhd prophylaxis to standard of care for acute leukemia patients

Conditions: Acute Lymphoblastic Leukemia (ALL) in Complete Remission; Acute Myeloid Leukemia (AML) in Remission

Summary: this randomized clinical trial will evaluate two approaches of gvhd prophylaxis; the standard of care gvhd prophylaxis regimen (methotrexate/calcineurin inhibitors) and post-transplant cyclophosphamide with calcineurin inhibitors for their efficacy as a new gvhd prophylaxis strategy.

an open-label randomized clinical trial will be performed. eligible patients are females and males, between 14 and 65 years undergoing allo-hct for treatment of acute leukemia (aml or all). patients must have a matching related peripheral blood stem cell donor. patients from or referred to the kfsh\&rc for allogeneic transplant consideration will be offered the opportunity to participate in this trial. treatment description: patients will be randomized on one of the arms; an intervention or a standard of care arm.

Eligibility criteria:
inclusion criteria: * patients with acute leukemias (aml, all) in morphologic complete remission with or without hematologic recovery * patients must have a fully matched (8/8) related donor willing to donate peripheral blood stem cells and must meet institutional criteria for donation * planned myeloablative conditioning regimen * cardiac function: ejection fraction at rest ≥ 50% by muga or tte * estimated creatinine clearance greater than 50 ml/minute * pulmonary function: dlco ≥ 50% (adjusted for hemoglobin), and fvc and fev1 ≥ 50% * liver function: total bilirubin \< 2x the upper limit of normal (unless elevated bilirubin is attributed to gilbert's syndrome) and alt/ast \< 2.5x the upper normal limit * signed informed consent exclusion criteria: * karnofsky or lansky performance score \< 70%. * active disease * patients with uncontrolled bacterial, viral, or fungal infections * presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated * patients seropositive for hiv-1 or -2 * patients seropositive for htlv-i or -ii * patients with active hepatitis b or c viral replication by pcr * women who are pregnant (positive serum or urine βhcg) or breastfeeding * females with childbearing potential (fcbp) or men who have sexual contact with fcbp unwilling to use effective forms of birth control or abstinence for one year after transplantation * history of uncontrolled autoimmune disease or on active treatment * patients with prior malignancies, except resected non-melanoma skin cancer or treated cervical carcinoma in situ; cancer treated with curative intent ≥ 5 years previously will be allowed; cancer treated with curative intent \< 5 years previously will not be allowed.

Keywords: sibling donor transplant allogeneic hematopoietic cell transplantation gvhd prophylaxis myeloablative regimen
to evaluate the safety, local tolerability, pk and pd of lde225 on sporadic superficial and nodular skin basal cell carcinomas (sbcc)

Conditions: Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

Summary: this was a double-blinded, randomized, vehicle-controlled study in sporadic superficial bcc (sbcc) and nodular bcc (nbcc) patients which consisted of a 21-day screening period, a treatment period of 6 weeks (topical 0.75% lde225 cream application b.i.d) ending with post treatment biopsies, as safety visit one week after final study drug administration (day 50), a visit on day 83 for excision of the treated bcc, and an end of study evaluation (day 90).


Eligibility criteria:
inclusion criteria: * patients with one histologically confirmed superficial and nodular basal cell carcinoma (8-20 mm) eligible for surgical excision on selected body areas (scalp, arm, frontal trunk, posterior trunk, upper legs) exclusion criteria: * previous treatment of the sbcc that are selected for treatment. * any systemic treatment which is known to affect bccs esp. cytostatic treatments, retinoids and photodynamic treatments. * dark-skinned persons whose skin color prevents readily assessment of skin reactions other protocol defined incl./excl. criteria may apply.

Keywords: basal cell carcinomas, sporadic, superficial and nodular, skin
a study to learn about whether bay h006689 causes an allergic reaction when applied as a topical gel in healthy participants

Conditions: Pain; Healthy Volunteers

Summary: researchers are looking for a better way to treat muscle and joint pain. researchers have seen that medicines which help reduce pain and inflammation could be safer when applied directly to the skin, called topical application, than when taken by mouth. however, recent studies have found that using these medicines on the skin can sometimes cause skin reactions such as redness, itching, or irritation in the area where the medicine is applied. however, reports of more serious side effects, affecting the entire body, from using these topical medicines are uncommon. the study treatment bayh006689 is under development to treat muscle and joint pain. in this study, participants will be healthy and will not benefit from bayh006689. however, the study will provide information on how to test bayh006689 in future studies in people with muscle and joint pain. the main purpose of this study is to check if bayh006689 topical gel causes any skin reactions in healthy participants. the skin reactions will be assessed using a scale. this scale will provide scores for redness, swelling, and other signs of skin irritation. in this study, researchers will randomly assign 3 sites, adjacent to each other, on the back of participants' bodies just below the shoulder blades. the following gels will be applied 10 times at these sites as a patch three times a week for 21 days and once after 14-17 days: * bayh006689 * placebo, which looks like the study drug but does not have any medicine in it. * 0.9 % saline each participant will be in the study for around 6 to 8 weeks. during this time they will: * receive assigned treatment gels at the identified skin sites * have their skin reaction symptoms assessed during the study, the doctors and their study team will: * check the medical history of the participants * check participants' health by performing urine tests * ask the participants questions about how they are feeling and what adverse events they are having an adverse event is any medical problem that a participant has during a study. doctors keep track of all adverse events, irrespective of whether they think they are related or not to the study treatment.


Eligibility criteria:
inclusion criteria: * healthy adult * is 18 years of age or older * free of any systemic or dermatological disorder that may interfere with results or increase risk of adverse events (aes) exclusion criteria: * has a condition and/or is using medications that may interfere with the study results * pregnant or planning to get pregnant or breastfeeding * is currently participating in any clinical testing
adjunct photodynamic therapy in chronic periodontitis among cigarette-smokers.

Conditions: Chronic Periodontitis; Smoking

Summary: this study evaluates the efficacy of scaling and root planing with and without adjunct antimicrobial photodynamic therapy (apdt) in the treatment of chronic periodontitis (cp) among cigarette-smokers and never-smokers.

the following inclusion criteria were entailed: (a) self-reported habitual cigarette-smokers; (b) self-reported never-smokers; (c) patients with cp (presence of at least 30% sites with ≥ 3 mm of cal and pd ≥ 3 mm 18, 19 ). the exclusion criteria were as follows: (a) patients with systemic diseases such as acquired immune deficiency syndrome/hiv and diabetes mellitus; (b) habitual smokeless tobacco product and alcohol users; (c) third molars and fractured teeth with embedded root remnants and edentulous individuals; (d) patients with misaligned teeth; and (e) patients that reported to have used antibiotics, non-steroidal anti-inflammatory drugs and/or steroids within the past 90 days. demographic information was collected using a questionnaire. cigarette-smokers (group-1) and never-smokers (group-2) with chronic periodontitis were included. treatment wise, these individuals were divided into two subgroups as follows: (a) srp alone and (b) srp with adjunct apdt. periodontal parameters (plaque index \[pi\], bleeding on probing \[bop\], clinical attachment loss \[cal\] and probing pocket depth ≥4mm \[pd\] were measured at baseline and at 1 month and 3 months' follow-up.

Eligibility criteria:
inclusion criteria: * self-reported habitual cigarette-smokers. * self-reported never-smokers. * patients with chronic periodontitis (presence of at least 30% sites with ≥ 3 mm of cal and pd ≥ 3 mm. exclusion criteria: * patients with systemic diseases such as acquired immune deficiency syndrome/hiv and diabetes mellitus. * habitual smokeless tobacco product and alcohol users. * third molars and fractured teeth with embedded root remnants and edentulous individuals. * patients with misaligned teeth. * patients that reported to have used antibiotics, non-steroidal anti-inflammatory drugs and/or steroids within the past 90 days.
exercise capacity evaluation in patients with non-rheumatic mitral valve prolapse (mvp)

Conditions: Mitral Valve Prolapse

Summary: mitral valve prolapse (mvp) is a relatively common cardial problem in which one or more of the leaflets of the mitral valve prolapse during systole into the left atrium. the disease is very heterogeneous and can vary from a benign disease with almost no impact on the patient's life to a severe cardiac problem with many complications and high mortality rate. the purpose of the study is to see if the investigators can find a relation between the severity of the mvp to the exercise capacity of the patient. the investigators also want to see if they can find a difference between the exercise capacity of mild mvp patients and healthy people. to evaluate the exercise capacity of the subjects the investigators use cardiopulmonary exercise testing (cpet). cpet is probably the best known way to get a full picture of the subject's functions during exercise. by combining gas exchange monitoring and ecg during a controlled exercise in which the subject reaches maximal effort, the test gives information about the cardiac, the pulmonary and the metabolic functions of the subject. this information can help identify if there is a problem to perform exercise properly and more specifically if the limitation is due to a cardiac, pulmonary or metabolic problem.

mitral valve prolapse (mvp) is a relatively common cardial problem in which one or more of the leaflets of the mitral valve prolapse during systole into the left atrium. the disease is very heterogeneous and can vary from a benign disease with almost no impact on the patient's life to a severe cardiac problem with many complications and high mortality rate . the purpose of the study is to see if the investigators can find a relation between the severity of the mvp to the exercise capacity of the patient. the investigators also want to see if they can find a difference between the exercise capacity of mild mvp patients and healthy people. to evaluate the exercise capacity of the subjects the investigators use cardiopulmonary exercise testing (cpet). cpet is probably the best known way to get a full picture of the subject's functions during exercise. by combining gas exchange monitoring and ecg during a controlled exercise in which the subject reaches maximal effort, the test gives information about the cardiac, the pulmonary and the metabolic functions of the subject. this information can help identify if there is a problem to perform exercise properly and more specifically if the limitation is due to a cardiac, pulmonary or metabolic problem.

Eligibility criteria:
inclusion criteria: * mvp diagnosis * signing consent form (by parents if the patient is a minor) exclusion criteria: * other congenital or acquired cardiac problems other than mvp. * patients with other diseases that can affect the exercise capacity.
a multicenter clinical trial of ingaron in pulmonary tuberculosis

Conditions: Respiratory Tuberculosis

Summary: the main purpose of testing: to confirm the effectiveness and safety of the drug ingaron when used in patients hospitalized at the research center for various reasons.

monitoring of a patient in a hospital is carried out daily by the attending physician during the entire period of the patient's stay at the research center. when prescribing the drug ingaron, the researcher must follow the instructions for use of the drug. as part of 4 control observations to assess effectiveness and safety: * 1st on the 1st day of using the drug ingaron and starting anti-tuberculosis therapy * 2nd on the 30th - 31st day of therapy * 3rd after 2 months of therapy * 4th (final) after 3 months of follow-up after each of the 3 visits, the research doctor saves the data necessary for further evaluation.

Eligibility criteria:
inclusion criteria: 1. age from 18 to 78 years inclusive 2. bacterioscopically and/or molecularly genetically verified diagnosis of tuberculosis 3. stay in the intensive phase of treatment 4. consent to inpatient anti-tuberculosis therapy until the end of participation in clinical observation exclusion criteria: 1. serious condition 2. pregnancy 3. breastfeeding 4. treatment with immunomodulatory drugs before inclusion in the observation program 5. presence of medical history of an allergic reaction or individual intolerance to the drug ingaron 6. severe diseases of the liver, kidneys (creatinine more than 150 mmol/l) 7. presence of contraindications to the administration of the drug ingaron 8. patients with hiv infection with a cd4 lymphocyte count less than 350 cells/ml

Keywords: respiratory tuberculosis interferon gamma
transcutaneous bilirubinometers in the community

Conditions: Jaundice, Neonatal

Summary: jaundice is the most frequent reason for readmission for healthy newborns after discharge from the nursery. in the capital health area, around 2.5% (315 babies in 2005) of all healthy newborns were admitted to the hospital for jaundice. although jaundice is very common, it is not always a benign condition. if left untreated, it can have devastating consequences including cerebral palsy and hearing loss. it is therefore critical to be able to identify the newborns at risk for severe jaundice. so far, heel puncture of blood collection has been the traditional method to monitor jaundice in newborns. this causes pain to infants, generates anxiety in parents, and consumes significant health care resources. the aim of this study is to evaluate the efficacy of a new and noninvasive screening tool, the transcutaneous bilirubinometer, in detecting babies in our communities who require hospital readmission. this study will demonstrate whether incorporating transcutaneous bilirubinometer in the home care program delivered by nurses of healthy beginning allows the early detection of babies at risk of developing severe jaundice at a lower cost and with less discomfort.


Eligibility criteria:
inclusion criteria: * all near term (35 and 36 weeks gestational age) and term (37 to 41 weeks) babies living in alberta capital health (ch) region * born at any capital health or caritas delivery facility(royal alexandra hospital, grey nuns community hospital, misericordia community hospital, sturgeon community hospital, fort saskatchewan health centre, and westview health centre) * discharged home from the nursery within 96 hours of life exclusion criteria: * babies who do not live in ch region * babies born at less than 35 weeks gestational age * babies initially admitted to a special care nursery (scn) or a neonatal intensive care unit (nicu) for more than 72 hours * babies born to opting-out mothers will also be excluded

Keywords: neonatal jaundice physiological neonatal jaundice neonatal hyperbilirubinemia transcutaneous bilirubinometer
risk of malignancy in endemic long standing nodular goitres: a prospective cohort study

Conditions: Incidence of Thyroid Cancer in Long Standing MNG

Summary: to determine the incidence of thyroid cancer in patients with long standing goitres presenting for surgery.

this is a prospective cohort study the objective is to determine the incidence of cancer in patients with long standing goitres( more than 10 years ) who present for surgery in khartoum teaching hopspital - sudan. introduction: goitre is endemic in sudan with prevalence ranging between 5-42% in different regions of the country. patients are referred for surgery only if they develop pressure symptoms. the incidence of thyroid carcinoma is high in endemic goitrous areas. determining the risk of cancer in patient with long standing goitres may help in early early referral and early surgical intervention. methods: this is prospective cohort study including 160 patients with long standing goitrers of 10 years or more who presented from march 2017 to september 2017 to khartoum teaching hospital-sudan

Eligibility criteria:
inclusion criteria: * all patients with long standing goitres of 10 years or more exclusion criteria: * non

Keywords: : goitre, long standing, malignant risk, incidental.